Results 231 to 240 of about 3,072,550 (265)

Pamufetinib (TAS-115) for chronic fibrosing interstitial lung diseases with a progressive phenotype: a double-blind, multicenter, phase 2b clinical trial. [PDF]

Am J Respir Crit Care Med
Okuda R, Nishioka Y, Kondoh Y, Tsubouchi K, Okamoto M, Nishiyama O, Sato S, Oishi K, Ishikawa N, Chiba H, Miyazaki Y, Homma S, Ogura T, Inoue Y, Azuma A.   +14 more
europepmc   +1 more source

Intelligent Automation Improved Efficiency in Pharmacovigilance Safety Signal Assessment

Clinical Pharmacology &Therapeutics, EarlyView.
Pharmacovigilance is the science involving the detection, assessment, understanding, and prevention of adverse events associated with drugs, biologics, or medical devices. In pharmacovigilance, information that suggests a new potential causal relationship between an intervention and an adverse event is called a safety signal. Following their detection,
Jeffrey Warner, Luis Henrique De Souza Teodoro, Anaclara Prada Jardim, Claudia Albera   +3 more
wiley   +1 more source

Interstitial Lung Disease in Children: Rare Genetic Variants Beyond Surfactant Dysfunction. [PDF]

Pediatr Pulmonol
Tabakçı SÖ, Akyan Soydaş ŞS, Tuğcu GD, Cinel G, Sağdıç AC, Özçelik U, Can Oksay S, Korkmaz Ç, Zirek F, Kekeç H, Gülen F, Hangül M, Özsezen B, Altıntaş DU, Çağlar HT, Başaran AE, Uyan ZS, Özdemir A, Ramaslı Gürsoy T, Yalçın E, Emiralioğlu N, Girit S, Kılınç AA, Çobanoğlu N, Şişmanlar Eyüboğlu T, Pekcan S, Gökdemir Y, Oğuz B, Orhan D, Ceylan AC, Kiper N.   +30 more
europepmc   +1 more source

Toward Fit‐for‐Purpose Data for Drug Assessment in Non‐small Cell Lung Cancer: A Core Dataset

Clinical Pharmacology &Therapeutics, EarlyView.
Considering the high unmet medical need in people with non‐small cell lung cancer (NSCLC), the drug assessment for targeted therapies often rely on small populations and single‐arm trials, challenging the evaluation by regulatory authorities, health technology assessment bodies (HTAb), and clinicians.
Geeske F. Grit, Maaike van Dartel, Laura Rodwell, Hanneke van der Woude, Cornelis Boersma, Peter G. M. Mol, Doranne Hilarius   +6 more
wiley   +1 more source

Association of ICD-10-Coded Pneumonia Events with Interstitial Lung Disease Outcomes in Patients with Rheumatoid Arthritis: A Large Database Retrospective Cohort. [PDF]

Adv Respir Med
Kosak Lopez E, Rodriguez Donís L, Lam J, Geller A, Leguizamon R, Vera Ricaurte M, Nethala P, Planchart Ferretto M, Fernandez-Wever ML, Martinez-Manzano JM, Pacheco E, Abdollahi S.   +11 more
europepmc   +1 more source

Exposure‐Response Analyses of Datopotamab Deruxtecan (Dato‐DXd), a TROP2‐Directed Antibody‐Drug Conjugate, in Advanced Non‐small Cell Lung Cancer

Clinical Pharmacology &Therapeutics, EarlyView.
Exposure‐response analyses supported a favorable benefit‐risk profile of Dato‐DXd at 6 mg/kg Q3W in patients with advanced nonsquamous NSCLC. Datopotamab deruxtecan (Dato‐DXd) is a trophoblast cell‐surface antigen‐2 (TROP2)‐directed antibody‐drug conjugate (ADC) that has demonstrated clinical activity in patients with NSCLC who have received prior ...
Ying Hong, Anna M. Mc Laughlin, Yuzhuo Pan, Sofia Friberg Hietala, Sophie Peigné, Michael Chargualaf, Zoey Tang, Diansong Zhou, Naoyuki Tajima, Malaz Abutarif, Tushar Garimella   +10 more
wiley   +1 more source

Autoantibodies in chronic non-infectious respiratory diseases: a scoping review. [PDF]

Front Immunol
Chow KL, Bekkers M, de Malmanche T, Patchett K, Wark PAB, Kaiko GE.   +5 more
europepmc   +1 more source

Association of COPD with adverse outcomes in heart failure patients with preserved ejection fraction

ESC Heart Failure, Volume 12, Issue 2, Page 799-808, April 2025.
Abstract We performed a systematic review and meta‐analysis to detect the impact of chronic obstructive pulmonary disease (COPD) on the prognosis of heart failure patients with preserved ejection fraction (HFpEF). We systematically screened eligible literature from three electronic databases, PubMed, EMBASE and Cochrane Library, up to April 2023.
Shuo Xu, Zhenbang Gu, Wengen Zhu, Shenghui Feng   +3 more
wiley   +1 more source

Prevalence Patterns of Children's Interstitial and Diffuse Lung Disease (chILD) in Colombia, 2016-2024. [PDF]

Pediatr Pulmonol
Buitrago AP, Buendía JA.
europepmc   +1 more source

Prevalence and incidence of interstitial lung diseases in systemic lupus erythematosus: systematic review and meta-analyses. [PDF]

Lupus Sci Med
Semmler JK, Davidsen JR, Adelhelm JBH, Fløjborg S, Voss A, Langkilde HZ.   +5 more
europepmc   +1 more source